PP_1170x120_10-25-21

Dr. Reddy’s Laboratories

Dr. Reddy’s teams to develop affordable and life-saving new drugs for neglected tropical diseases

Dr. Reddy’s teams to develop affordable and life-saving new drugs for neglected tropical diseases

HYDERABAD, India — Dr. Reddy’s and Aurigene Pharmaceutical Services Limited, a contract research, development and manufacturing services organization and fully owned stepdown subsidiary of Dr. Reddy’s announce a Memorandum of Understanding (MoU) with the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development organization that develops new therapeutic solutions for neglected diseases and

Dr. Reddy’s unveils generic Allegra-D 24HR

Dr. Reddy’s unveils generic Allegra-D 24HR

PRINCETON, N.J.  — Dr. Reddy’s Laboratories announced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoephedrine HCl 240 mg Extended Release Tablets, USP, the store-brand equivalent of Allegra-D 24 HR in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA). “The launch of Dr. Reddy’s Fexofenadine HCl 180

Dr. Reddy’s launches methylprednisolone sodium succinate for injection

Dr. Reddy’s launches methylprednisolone sodium succinate for injection

PRINCETON, N.J.— Dr. Reddy’s announced the launch of methylprednisolone sodium succinate for injection, USP, the generic equivalent of SOLU-MEDROL (methylprednisolone sodium succinate for injection, USP) in the U.S. Market approved by the U.S. Food and Drug Administration (USFDA). The SOLU-MEDROL brand and generic had U.S. sales of approximately $144 million MAT for the most recent

Dr. Reddy’s Colicchio discusses workforce optimization

Dr. Reddy’s Colicchio discusses workforce optimization

Vincent Colicchio is vice president of supply chain and external manufacturing for Dr. Reddy’s Laboratories North America. In this interview he discusses optimizing the industry’s workforce, facilities and processes, including measures to avoid drug shortages. CDR: What do you see as workforce needs and training for generic drug manufacturing? COLICCHIO: For generic drug manufacturing, there

Dr. Reddy’s unveils generic Akovaz

Dr. Reddy’s unveils generic Akovaz

PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of Ephedrine Sulfate Injection USP, 50 mg/mL, a therapeutic equivalent generic version of Akovaz (ephedrine sulfate injection) Injection, 50 mg/mL approved by the U.S. Food and Drug Administration. The Akovaz brand and generic market had U.S. sales of approximately $67.5 million MAT for the most recent

Dr. Reddy’s Laboratories Canada announces the launch of Reddy-Lenalidomide

Dr. Reddy’s Laboratories Canada announces the launch of Reddy-Lenalidomide

MISSISSAUGA, Ontario — Dr. Reddy’s Laboratories today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada. “Our launch of Reddy-Lenalidomide represents our firm commitment to providing

Dr. Reddy’s offers timely and proactive initiatives

Dr. Reddy’s offers timely and proactive initiatives

PRINCETON, N.J. — Dr. Reddy’s path to excelling in the manufacture of complex generics and biosimilars depends on its successful filing for new drugs — be these formulations or active pharmaceutical ingredients (APIs). In fiscal 2020, the company filed eight new Abbreviated New Drug Applications (ANDAs) with the Food and Drug Administration. As of March

Dr. Reddy’s rolls out generic version of Ciprodex

Dr. Reddy’s rolls out generic version of Ciprodex

PRINCETON, N.J. – Dr. Reddy’s  announced the launch of ciprofloxacin 0.3% and dexamethasone 0.1% Otic Suspension, USP, a therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring

Brill: Dr. Reddy’s meeting challenges

Brill: Dr. Reddy’s meeting challenges

PRINCETON, N.J. — When the COVID-19 pandemic hit, the generic drug industry faced many challenges, says Vanessa Brill, vice president and regional general counsel for the Americas at Dr. Reddy’s Laboratories. For Dr. Reddy’s, the challenges included finding ways to continue to produce drugs at manufacturing facilities that had to operate at decreased capacity out

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

Dr. Reddy’s enters into a licensing agreement with Gilead Sciences for Remdesivir

PRINCETON, N.J.— Dr. Reddy’s announced that it has entered into a non-exclusive Licensing Agreement with Gilead Sciences that will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for COVID-19, in 127 countries including India. Dr. Reddy’s will receive technology transfer from Gilead for manufacturing of this

Dr. Reddy’s gets approval for their NDA, Elyxyb (celecoxib oral solution) 25 mg/mL, in the U.S.

Dr. Reddy’s gets approval for their NDA, Elyxyb (celecoxib oral solution) 25 mg/mL, in the U.S.

PRINCETON, N.J. —Dr. Reddy’s announced approval of Elyxyb (celecoxib oral solution 25 mg/mL) by the U.S. Food and Drug Administration (USFDA). Elyxyb (previously known as DFN-15) is indicated for the acute treatment of migraine with or without aura in adults. Elyxyb is the latest product emerging from Dr. Reddy’s portfolio of successful acute migraine treatments.

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

Dr. Reddy’s Laboratories announces the launch of desmopressin acetate injection

PRINCETON, N.J. — Dr. Reddy’s announced the launch of desmopressin acetate injection USP, 4 mcg/mL Single-dose Ampules, a therapeutic equivalent generic version of DDAVP (desmopressin acetate) Injection , 4 mcg/mL, approved by the U.S. Food and Drug Administration (USFDA). The DDAVP (desmopressin acetate) Injection USP brand and generic market had U.S. sales of approximately $20.9

Dr. Reddy’s rolls out pre-filled naloxone syringes

Dr. Reddy’s rolls out pre-filled naloxone syringes

PRINCETON,  N.J.— Dr. Reddy’s Laboratories announced Monday the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring our second product to market that has been

1 2 3
Adheris Health